Chunya Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chunya Ma has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Yang Yu
Department of Transfusion Medicine The First Medical Center of Chinese PLA General Hospital Beijing China
5 shared publications Deqing Wang
Department of Blood Transfusion, First Medical Center of Chinese PLA General Hospital, Beijing, China
2 shared publicationsLihui Fu
Department of Blood Transfusion Medicine The First Medical Center of Chinese PLA General Hospital Beijing China
2 shared publicationsLu Yang
Department of Blood Transfusion, First Medical Center of Chinese PLA General Hospital, Beijing, China
2 shared publicationsShufang Wang
Department of Blood Transfusion, First Medical Center of Chinese PLA General Hospital, Beijing, China
2 shared publicationsXiaozhen Guan
Department of Blood Transfusion Medicine The First Medical Center of Chinese PLA General Hospital Beijing China
2 shared publications
Latest Publications
- Open Access
Diagnosis of Acute Hemolytic Transfusion Reaction Caused by Cold Reactive Anti‐P1 Antibody: A Case Report
Anti‐P1 alloantibody is predominantly an immunoglobulin M class, cold reactive antibody that is non‐reactive at 37°C in routine pre‐transfusion serology and thus generally regarded as clinically insignificant. However, rare clinically significant anti‐P1 antibodies can cause an acute hemolytic transfusion reaction (AHTR), and routine pre‐transfusion testing at 37°C may miss such antibodies. We report a case of AHTR caused by an anti‐P1 antibody detectable only at 4°C, which evaded detection by unexpected antibody screening performed at 37°C. A 65‐year‐old woman with blood group B, RhD positive developed AHTR within 24 h following red blood cell transfusion. She presented with coffee‐colored urine, markedly elevated bilirubin and lactate dehydrogenase concentrations, and a progressive decline in hemoglobin concentrations. Pre‐transfusion antibody screening at 37°C was negative. A retrospective serological analysis identified anti‐P1 exclusively at 4°C, which was confirmed by pigeon egg white inhibition. The patient was P1 negative; incompatibility occurred only with the P1‐positive donor unit. After transfusion of P1 antigen‐negative red blood cells, the hemolysis resolved and hemoglobin concentrations recovered. In patients with a repeated transfusion history, serological testing at 37°C and 4°C, in conjunction with antigen‐matched selection, is essential to prevent AHTR caused by clinically significant cold reactive antibodies.
Open AccessDiagnosis of Acute Hemolytic Transfusion Reaction Caused by Cold Reactive Anti‐P1 Antibody: A Case Report
Anti‐P1 alloantibody is predominantly an immunoglobulin M class, cold reactive antibody that is non‐reactive at 37°C in routine pre‐transfusion serology and thus generally regarded as clinically insignificant. However, rare clinically significant anti‐P1 antibodies can cause an acute hemolytic transfusion reaction (AHTR), and routine pre‐transfusion testing at 37°C may miss such antibodies. We report a case of AHTR caused by an anti‐P1 antibody detectable only at 4°C, which evaded detection by unexpected antibody screening performed at 37°C. A 65‐year‐old woman with blood group B, RhD positive developed AHTR within 24 h following red blood cell transfusion. She presented with coffee‐colored urine, markedly elevated bilirubin and lactate dehydrogenase concentrations, and a progressive decline in hemoglobin concentrations. Pre‐transfusion antibody screening at 37°C was negative. A retrospective serological analysis identified anti‐P1 exclusively at 4°C, which was confirmed by pigeon egg white inhibition. The patient was P1 negative; incompatibility occurred only with the P1‐positive donor unit. After transfusion of P1 antigen‐negative red blood cells, the hemolysis resolved and hemoglobin concentrations recovered. In patients with a repeated transfusion history, serological testing at 37°C and 4°C, in conjunction with antigen‐matched selection, is essential to prevent AHTR caused by clinically significant cold reactive antibodies.
- Open Access
A Rare Case of Delayed Hemolytic Transfusion Reaction Caused by Anti‐Ku: Laboratory Diagnosis and Clinical Management
This study presents a rare case of delayed hemolytic transfusion reaction (DHTR) induced by anti‐Ku. The patient was admitted due to recurrence of ovarian cancer. She had experienced unexplained anemia for more than 20 years but had no anemia in the past 10 years. She had been pregnant four times and given birth to four babies without blood transfusions. Pre‐transfusion examinations showed that her blood group was A and RhD positive, and the unexpected antibody screening test was weakly reactive. She received two red blood cell transfusions and then developed unexplained anemia, with a hemoglobin decrease from 122 to 88 g/L. The unexpected antibody screening result changed to strongly positive, and she returned positive direct anti‐human globulin test and major incompatible matching results. The homozygous mutation 715G > T was identified in exon 7 of the KELL gene, which is associated with a rare blood group phenotype known as K 0 . The patient produced anti‐Ku antibodies, leading to a DHTR. Extravascular hemolysis was controlled through the administration of immunoglobulin and erythropoietin, leading to the correction of anemia. Her hemoglobin concentration was 105 g/L upon discharge from the hospital. In the management of blood transfusion for patients with rare blood types, a comprehensive analysis is required, taking into account the specificity of high‐frequency antibodies produced by the patient, the types and strength of these antibodies, as well as the clinical demand for blood. When necessary, a short‐term, adequate transfusion of minimally incompatible blood may be administered, along with intravenous immunoglobulin and erythropoietin to correct hemolysis and anemia.
Open AccessA Rare Case of Delayed Hemolytic Transfusion Reaction Caused by Anti‐Ku: Laboratory Diagnosis and Clinical Management
This study presents a rare case of delayed hemolytic transfusion reaction (DHTR) induced by anti‐Ku. The patient was admitted due to recurrence of ovarian cancer. She had experienced unexplained anemia for more than 20 years but had no anemia in the past 10 years. She had been pregnant four times and given birth to four babies without blood transfusions. Pre‐transfusion examinations showed that her blood group was A and RhD positive, and the unexpected antibody screening test was weakly reactive. She received two red blood cell transfusions and then developed unexplained anemia, with a hemoglobin decrease from 122 to 88 g/L. The unexpected antibody screening result changed to strongly positive, and she returned positive direct anti‐human globulin test and major incompatible matching results. The homozygous mutation 715G > T was identified in exon 7 of the KELL gene, which is associated with a rare blood group phenotype known as K 0 . The patient produced anti‐Ku antibodies, leading to a DHTR. Extravascular hemolysis was controlled through the administration of immunoglobulin and erythropoietin, leading to the correction of anemia. Her hemoglobin concentration was 105 g/L upon discharge from the hospital. In the management of blood transfusion for patients with rare blood types, a comprehensive analysis is required, taking into account the specificity of high‐frequency antibodies produced by the patient, the types and strength of these antibodies, as well as the clinical demand for blood. When necessary, a short‐term, adequate transfusion of minimally incompatible blood may be administered, along with intravenous immunoglobulin and erythropoietin to correct hemolysis and anemia.
- 23 November 2023
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 31 (1) , 41-47
Application of anti-D immunoglobulin in D-negative pregnant women in China
- 23 November 2023
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 31 (1) , 41-47
Application of anti-D immunoglobulin in D-negative pregnant women in China
- 2 April 2020
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 35 (3) , 206-216
Protein spectrum changes in exosomes after therapeutic plasma exchange in patients with neuromyelitis optica
Introduction: Neuromyelitis optica (NMO) is an autoimmune disease with a high rate of blindness and positive for the detection of aquaporin‐4 antibody (AQP4) in most patients. NMO acute attacks are managed by high‐doses of intravenous methylprednisolone followed by oral taper, and if symptoms fail to resolve, therapeutic plasma exchange (TPE) is added. TPE can remove pathological antibodies and inflammatory factors leading to clinical improvement.Methods: A total of 40 TPE fluid collections from the first to fifth TPE treatments were obtained from eight patients. Exosomes were isolated by ultracentrifugation. Mass spectrometry analyses were used to compare protein change in TPE fluid collection exosomes after the first to the fifth TPE treatments in these patients.Results: We detected 647 exosome proteins through data‐independent acquisition analysis. It was found that some unknown functional antibody fragments and complement pathway proteins decreased after TPE treatment. The results revealed a significant involvement of the following two key pathways: the primary immunodeficiency and systemic lupus erythematosus that may be associated with NMO pathophysiology and TPE treatment efficacy (P < .05). A series of complement proteins may contribute to NMO; in addition, the following proteins increased with plasma exchange: complement factor H‐related protein 5, bridging integrator 2, neuroplastin, pigment epithelium‐derived factor, ficolin‐1, extracellular matrix protein 1, and fatty acid‐binding protein 5.Conclusion: Our study may provide a new perspective on the pathogenesis and treatment efficacy of NMO.
- 2 April 2020
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 35 (3) , 206-216
Protein spectrum changes in exosomes after therapeutic plasma exchange in patients with neuromyelitis optica
Introduction: Neuromyelitis optica (NMO) is an autoimmune disease with a high rate of blindness and positive for the detection of aquaporin‐4 antibody (AQP4) in most patients. NMO acute attacks are managed by high‐doses of intravenous methylprednisolone followed by oral taper, and if symptoms fail to resolve, therapeutic plasma exchange (TPE) is added. TPE can remove pathological antibodies and inflammatory factors leading to clinical improvement.Methods: A total of 40 TPE fluid collections from the first to fifth TPE treatments were obtained from eight patients. Exosomes were isolated by ultracentrifugation. Mass spectrometry analyses were used to compare protein change in TPE fluid collection exosomes after the first to the fifth TPE treatments in these patients.Results: We detected 647 exosome proteins through data‐independent acquisition analysis. It was found that some unknown functional antibody fragments and complement pathway proteins decreased after TPE treatment. The results revealed a significant involvement of the following two key pathways: the primary immunodeficiency and systemic lupus erythematosus that may be associated with NMO pathophysiology and TPE treatment efficacy (P < .05). A series of complement proteins may contribute to NMO; in addition, the following proteins increased with plasma exchange: complement factor H‐related protein 5, bridging integrator 2, neuroplastin, pigment epithelium‐derived factor, ficolin‐1, extracellular matrix protein 1, and fatty acid‐binding protein 5.Conclusion: Our study may provide a new perspective on the pathogenesis and treatment efficacy of NMO.